Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04755244
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-14
First Post:
2021-02-11
Brief Title:
A Study of Evorpacept ALX148 With Venetoclax and Azacitidine for Acute Myeloid Leukemia ASPEN-05
Sponsor:
ALX Oncology Inc
Organization:
ALX Oncology Inc
Study Overview
Official Title:
A Phase 12 Study of Evorpacept ALX148 in Combination With Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia AML ASPEN-05
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase 12 clinical study will evaluate evorpacept ALX148 in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia AML
Detailed Description:
The Phase 1 will consist of a dose escalation of evorpacept ALX148 in combination with venetoclax and azacitidine to evaluate safety and tolerability and to identify the recommended Phase 2 dose of evorpacept ALX148 in combination with venetoclax and azacitidine The Phase 2 will evaluate the efficacy of evorpacept ALX148 in combination with venetoclax and azacitidine for patients with AML
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None